Clovis Oncology Inc. (NASDAQ:CLVS)’s share price fell 6% during trading on Tuesday . The company traded as low as $14.14 and last traded at $14.14, with a volume of 313,404 shares trading hands. The stock had previously closed at $15.04.

A number of brokerages have recently commented on CLVS. Piper Jaffray Cos. reissued a “hold” rating on shares of Clovis Oncology in a research note on Sunday, May 8th. Vetr downgraded shares of Clovis Oncology from a “buy” rating to a “hold” rating and set a $17.66 target price on the stock. in a research note on Tuesday, June 7th. Mizuho reaffirmed a “hold” rating on shares of Clovis Oncology in a report on Wednesday, April 13th. Zacks Investment Research raised shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Thursday, April 14th. Finally, JPMorgan Chase & Co. lowered shares of Clovis Oncology from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $42.00 to $15.00 in a report on Wednesday, April 13th. Seven analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $29.25.

The company’s market capitalization is $592.66 million. The firm has a 50-day moving average of $14.14 and a 200 day moving average of $16.51.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.39) by $0.22. During the same quarter last year, the firm earned ($1.86) earnings per share. Clovis Oncology’s revenue was up NaN% compared to the same quarter last year. On average, equities research analysts predict that Clovis Oncology Inc. will post ($8.00) earnings per share for the current year.

Other hedge funds have bought and sold shares of the company. Rhumbline Advisers boosted its stake in Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares during the period. California State Teachers Retirement System boosted its stake in Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares during the period. Finally, Trexquant Investment LP acquired a new stake in Clovis Oncology during the fourth quarter worth about $3,170,000.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.